

## The RxAir360 Prototype Passes Hydrostatic Testing

The 1st patented clinical monoplace hyperbaric chamber, specifically tailored to fit in a physician's exam room, has a completed prototype.



Recent developments at RxAir360 Inc. include the successful passage of our prototype through the hydrostatic test, witnessed by an Inspector from the American Society of Mechanical Engineers (ASME). We are currently in the process of compiling the requisite documentation for submission to the FDA through FDA 510k Consultants, LLC. Additionally, we are investigating our eligibility for the "Breakthrough Device Program," which has the potential to expedite the FDA clearance process.

Our ongoing fundraising endeavors are aligned with the impending closure of the current fundraising round by November 15th, facilitated by our attorneys at ArentFox Schiff. Furthermore, we have engaged a third-party Valuation company to furnish our valuation next month, encompassing the finalization of our prototype and the imminent FDA submission.

We are poised to initiate a new funding round with an adjusted share price or explore term agreements with larger investors to facilitate our readiness for sales, marketing, production, expansion, and recruitment.



Patients will be comfortably seated with four viewports: one on each side, one at the front, and one above.

## **About the Company**

RxAir360 Inc. is poised to enhance patient access to high-quality Hyperbaric Oxygen Therapy (HBOT) by leveraging our patented design and upright seating. This innovative approach enables the effortless integration of our advanced medical device into physicians' offices, thus enhancing the delivery of medical care.

We are committed to expanding the availability of affordable hyperbaric oxygen therapy (HBOT) for all patient demographics, and to establishing a supplementary revenue stream for physicians operating within their private practices who have not yet engaged in clinical hyperbaric therapy.